TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7485935

Group type: EXPERIMENTAL
Intervention: Ginger BP 0.5g
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ginger BP 1.0g
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 108
Study: 1973591

Group type: EXPERIMENTAL
Intervention: Somatostatin (ST) 4.2 micrograms/min for 72 hours
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vasopressin (VP) 0.4 IU/min for 72 hours
Number of subjects: 54
Study: 6785794

Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 30

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 30
Study: 29857780

Group type: EXPERIMENTAL
Intervention: 1% N-chlorotaurine (NCT) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1% N-chlorotaurine (NCT) inhaled solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) inhaled solution
Number of subjects: 24
Study: 27163497

Group type: EXPERIMENTAL
Intervention: Orteronel 400 mg with a low-fat meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Orteronel 400 mg with a high-fat meal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Orteronel 400 mg under fasting conditions
Number of subjects: 36
Study: 25059340

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) prior to TAVI
Number of subjects: 310

Group type: COMPARATOR
Intervention: No PCI (control arm)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 310
Study: 22561565

Group type: EXPERIMENTAL
Intervention: Systematic self-management education
Number of subjects: 248

Group type: COMPARATOR
Intervention: Routine community education (Control)
Number of subjects: 248
Study: 20931154

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 62
Study: 17653960

Group type: EXPERIMENTAL
Intervention: 10 mg topical testosterone therapy daily (2 cm Andro‐Feme cream)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16173911

Group type: EXPERIMENTAL
Intervention: Advice plus behavioral counseling during primary care visits
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Advice plus behavioral counseling that included telephone contact and behavioral classes
Number of subjects: 874

Group type: COMPARATOR
Intervention: Physician advice (control group)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: All treatment arms (including control)
Number of subjects: 874
Study: 11902621

Group type: EXPERIMENTAL
Intervention: Downward comparisons with worse-off others
Number of subjects: 0
Study: 9850940

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8084808

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propranolol (5 persons) in patients with low K value
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acebutolol (7 persons) in patients with low K value
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (12 normal subjects)
Number of subjects: 31
Study: 2510264

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.d.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 91
Study: 806790

Group type: EXPERIMENTAL
Intervention: Lipostabil
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lipostabil forte
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo preparations
Number of subjects: 73
Study: 29699518

Group type: COMPARATOR
Intervention: Ophthalmic viscosurgical device (OVD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroimplantation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 27929610

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg over 40 minutes)
Number of subjects: 34
Study: 25185507

Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) assessment by practitioners
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) diagnostic studies
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) assessment by practitioners with >400 studies
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) assessment by experts involved in the Chicago Classification system
Number of subjects: 36
Study: 23525964

Group type: EXPERIMENTAL
Intervention: PTQ™
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Durasphere(®)
Number of subjects: 35
Study: 21734063

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered with HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Hepatitis B vaccine administered alone (HepB group)
Number of subjects: 148
Study: 19712717

Group type: EXPERIMENTAL
Intervention: flavored solution consumed prior to 30 min running exercise
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: flavored solution merely tasted prior to 30 min running exercise
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: exercise-related gastrointestinal distress
Number of subjects: 58
Study: 16672064

Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel (1.1 g applied for 30 minutes)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (1.1 g applied for 30 minutes)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15231423

Group type: EXPERIMENTAL
Intervention: Dysphagia intervention 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysphagia intervention 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11230783

Group type: EXPERIMENTAL
Intervention: L-NMMA (0.1 mg/kg/min) during insulin infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin infusion (40 mU/m2/min for young, 34 mU/m2/min for old)
Number of subjects: 20
Study: 9259113

Group type: EXPERIMENTAL
Intervention: Sulodexide (Sdx, 50 mg bid orally for 6 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Pentoxifylline (Ptx, 400 mg tid orally for six months)
Number of subjects: 86
Study: 7653754

Group type: EXPERIMENTAL
Intervention: Open hernia repair under local infiltration block (group A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Laparoscopic hernia repair under general anaesthesia (group B)
Number of subjects: 59
Study: 2670605

Group type: EXPERIMENTAL
Intervention: VMCP/VBAP (n = 42)
Number of subjects: 86

Group type: COMPARATOR
Intervention: MP (n = 44)
Number of subjects: 86
Study: 576833

Group type: EXPERIMENTAL
Intervention: Reproterol (Bronchspasmin) administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orciprenaline administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Number of subjects: 0
Study: 31954186

Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 20
Study: 31189165

Group type: EXPERIMENTAL
Intervention: ECHO
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: QuickOpt
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nominal AV/VV
Number of subjects: 124
Study: 28707086

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and carboxymethylcellulose (HA‐CMC)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Hyaluronic acid and hydroxyethyl starch (HA‐HES)
Number of subjects: 77
Study: 24936126

Group type: COMPARATOR
Intervention: ETV 0.5 mg daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ETV 1 mg daily
Number of subjects: 59
Study: 21703801

Group type: EXPERIMENTAL
Intervention: Standard-length catheters (SC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long catheters (LC)
Number of subjects: 100
Study: 20171839

Group type: EXPERIMENTAL
Intervention: PEDro total score
Number of subjects: 9456

Group type: EXPERIMENTAL
Intervention: Individual scale items contributing to PEDro total score
Number of subjects: 9456
Study: 18404563

Group type: EXPERIMENTAL
Intervention: Mentha piperita oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cuminum cyminum oil
Number of subjects: 0
Study: 15842263

Group type: EXPERIMENTAL
Intervention: Delayed-immediate protocol (Im)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed protocol (De)
Number of subjects: 46
Study: 12749439

Group type: EXPERIMENTAL
Intervention: Urinary LH‐timed endometrial and blood sampling
Number of subjects: 68
Study: 10505810

Group type: EXPERIMENTAL
Intervention: Polishing of the exposed root surface at slow speed with a rubber cup and prophylaxis paste for 60 seconds
Number of subjects: 10

Group type: COMPARATOR
Intervention: Root planing of the exposed root surface with a sharp curet
Number of subjects: 10
Study: 7603605

Group type: EXPERIMENTAL
Intervention: sCT suppositories at the dose of 100 UI/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sCT suppositories at the dose of 200 UI every other day
Number of subjects: 30
Study: 2234829

Group type: EXPERIMENTAL
Intervention: Near retinoscopy (NEAR) method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nott retinoscopy with DOG target
Number of subjects: 0
Study: 355027

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30893166

Group type: EXPERIMENTAL
Intervention: Combination of sublative bipolar fractional radiofrequency (FRF) and 0.1% topical tretinoin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sublative bipolar fractional radiofrequency (FRF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.1% topical tretinoin
Number of subjects: 18
Study: 28416587

Group type: EXPERIMENTAL
Intervention: Inhaled long-acting beta2-agonist (vilanterol 25 µg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (fluticasone furoate 100 µg)
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Combination therapy (fluticasone furoate 100 µg and vilanterol 25 µg)
Number of subjects: 16485

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 16485
Study: 26088809

Group type: EXPERIMENTAL
Intervention: Private pour-flush latrines shared by multiple households
Number of subjects: 760

Group type: COMPARATOR
Intervention: Existing shared private latrines in poor sanitary conditions
Number of subjects: 760
Study: 23315402

Group type: EXPERIMENTAL
Intervention: Oral feedback with written information
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral feedback only
Number of subjects: 72
Study: 21977857

Group type: EXPERIMENTAL
Intervention: Chinese medicine plus rehabilitation
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chinese medicine plus acupuncture
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chinese medicine and acupuncture plus rehabilitation
Number of subjects: 134

Group type: COMPARATOR
Intervention: Western medicine piracetam
Number of subjects: 134
Study: 19828234

Group type: COMPARATOR
Intervention: Poorly vascularized tumors (group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Well vascularized tumors (group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Presence of poorly vascularized tumor at CEUS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CEUS enhancement pattern
Number of subjects: 42
Study: 17074146

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin, clopidogrel)
Number of subjects: 120
Study: 15639697

Group type: COMPARATOR
Intervention: Rosuvastatin 80 mg/d alone (n = 69)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d (n = 75)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d
Number of subjects: 147

Group type: COMPARATOR
Intervention: Rosuvastatin 80 mg/d alone
Number of subjects: 147
Study: 11508705

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg) in athletes
Number of subjects: 0
Study: 10332375

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer materials (Fuji II LC, Photac-Fil, and Vitremer)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (Dyract)
Number of subjects: 80

Group type: COMPARATOR
Intervention: All materials (including control)
Number of subjects: 80
Study: 8500310

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including worksite, public site, mass mail, telephone, media, and referral strategies.
Number of subjects: 73000
Study: 3325092

Group type: EXPERIMENTAL
Intervention: Nocturnal dosing with levodopa
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30508987

Group type: EXPERIMENTAL
Intervention: Inflatable balloon catheter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balloon-less catheter
Number of subjects: 60
Study: 27349359

Group type: EXPERIMENTAL
Intervention: Feedback device (CPRmeter)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No feedback device
Number of subjects: 60
Study: 24419482

Group type: EXPERIMENTAL
Intervention: intervention diet
Number of subjects: 56

Group type: COMPARATOR
Intervention: control diet
Number of subjects: 56
Study: 22230825

Group type: EXPERIMENTAL
Intervention: TEAMcare program
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 20919606

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 7.2%‐tretinoin 0.025% gel (CTG) combination product
Number of subjects: 26

Group type: COMPARATOR
Intervention: Separate daily applications of clindamycin phosphate gel 1% and tretinoin cream 0.025% (C gel + T cream)
Number of subjects: 26
Study: 18263673

Group type: EXPERIMENTAL
Intervention: Circular track
Number of subjects: 27

Group type: COMPARATOR
Intervention: Straight track
Number of subjects: 27
Study: 15735198

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with amputation
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with poor visual acuity
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with macrovascular disease
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening levels of nephropathy
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening levels of neuropathy
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening levels of retinopathy
Number of subjects: 3711

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with worsening visual acuity
Number of subjects: 3711
Study: 12538365

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 5 mg kg(‐1) h(‐1) (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group C)
Number of subjects: 45
Study: 11053824

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine (PC) coating of the extracorporeal circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no coating)
Number of subjects: 20
Study: 8805887

Group type: EXPERIMENTAL
Intervention: Silver sulphadiazine and chlorhexidine impregnated CVC (SSD/CVC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard triple lumen CVC (STD/CVC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fibrin Analysing System (FAS) brush
Number of subjects: 54
Study: 1640003

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non-FH primary hypercholesterolemia
Number of subjects: 66
Study: 6234015

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.05 mg/kg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cyproterone acetate (5 mg daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isotretinoin + Cyproterone acetate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 27
Study: 31084761

Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (Ktrans, Kep, Ve, Vp, area under the curve, peak, time-to-peak)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (minimum Vp)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (Ve, Vp, time-to-peak)
Number of subjects: 38
Study: 30059420

Group type: EXPERIMENTAL
Intervention: Inferior turbinate reduction during SRP operation
Number of subjects: 32

Group type: COMPARATOR
Intervention: No inferior turbinate reduction during SRP operation
Number of subjects: 32
Study: 26748629

Group type: EXPERIMENTAL
Intervention: Pancrelipase replacement therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional pancreatic enzyme supplementation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Crossover to pancrelipase replacement therapy upon NAFLD diagnosis in control group
Number of subjects: 57
Study: 24561732

Group type: EXPERIMENTAL
Intervention: CS Reducer implantation
Number of subjects: 23
Study: 22413808

Group type: EXPERIMENTAL
Intervention: Insulin glargine therapy
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose > 10 mmol/l at week 6/8 or week 12
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose < 8.9 mmol/l at week 6/8 or week 12
Number of subjects: 1036
Study: 19237681

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (upper‐limb ischemia 6 times a day for 1 month)
Number of subjects: 30
Study: 16769171

Group type: EXPERIMENTAL
Intervention: Duloxetine for 12 weeks
Number of subjects: 1913

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 1913
Study: 15126526

Group type: EXPERIMENTAL
Intervention: L-T(4) replacement therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11486120

Group type: EXPERIMENTAL
Intervention: Trunk restraint (using a harness)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Unrestrained reaching
Number of subjects: 11
Study: 9926059

Group type: EXPERIMENTAL
Intervention: Intensive community care
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 138
Study: 7803416

Group type: EXPERIMENTAL
Intervention: Omentum group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Internal mammary artery group
Number of subjects: 36

Group type: COMPARATOR
Intervention: No wrap group
Number of subjects: 36
Study: 3388180

Group type: EXPERIMENTAL
Intervention: General anesthesia with parenteral morphine (GA group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia combined with epidural bupivacaine and epidural morphine (EP group)
Number of subjects: 100
Study: 30142849

Group type: EXPERIMENTAL
Intervention: Ultralow-dose CT (ULDCT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard low-dose CT (LDCT)
Number of subjects: 57
Study: 27085251

Group type: EXPERIMENTAL
Intervention: Codrituzumab 1600mg biweekly
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 25355667

Group type: EXPERIMENTAL
Intervention: Aversive events occurring in the past
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aversive events occurring in the future
Number of subjects: 0
Study: 23887766

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 12 mg triamcinolone acetonide at the end of surgery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no steroid injection)
Number of subjects: 54
Study: 20002501

Group type: EXPERIMENTAL
Intervention: AmB+Fluc400
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AmB+Fluc800
Number of subjects: 64

Group type: COMPARATOR
Intervention: AmB alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fluconazole (800 mg/day)
Number of subjects: 64
Study: 18568181

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazapril (CCB/ACEI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/benazapril
Number of subjects: 0
Study: 15966653

Group type: EXPERIMENTAL
Intervention: Polymer instrument without local anesthesia (LA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbide bur with local anesthesia (LA)
Number of subjects: 20
Study: 12829925

Group type: EXPERIMENTAL
Intervention: Low-dose calcitriol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard immunosuppressive therapy)
Number of subjects: 0
Study: 10202235

Group type: EXPERIMENTAL
Intervention: Treatment with antibiotics
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 80
Study: 9199120

Group type: EXPERIMENTAL
Intervention: Combined method (surgery and radiotherapy) with moderate postoperative dose of irradiation (5500-6000 cGy)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group treated by radical neck dissection (RND), modified neck dissection (MND), or regional modified neck dissection (RMND) with moderate postoperative dose of irradiation (5000-5500 cGy)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Exclusively irradiated group
Number of subjects: 213
Study: 1946180

Group type: EXPERIMENTAL
Intervention: Ordinary syringe (4 IU/ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Injection pen (12 IU/ml)
Number of subjects: 14
Study: 7180061

Group type: EXPERIMENTAL
Intervention: Preventive programme
Number of subjects: 2023

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2023
Study: 30871233

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet (n = 38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control diet (n = 37)
Number of subjects: 75
Study: 27709277

Group type: EXPERIMENTAL
Intervention: DWI‐MRE with Buscopan
Number of subjects: 30

Group type: COMPARATOR
Intervention: DWI‐MRE without Buscopan
Number of subjects: 30